Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 537324, 7 pages
http://dx.doi.org/10.1155/2014/537324
Review Article

Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?

Department of Rheumatology, University Hospital Saint-Etienne, 42055 Saint-Etienne Cedex, France

Received 25 October 2013; Accepted 10 February 2014; Published 12 March 2014

Academic Editor: Jean Sibilia

Copyright © 2014 Delphine Dénarié et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. M. Abdel-Nasser, J. J. Rasker, and H. A. Valkenburg, “Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis,” Seminars in Arthritis and Rheumatism, vol. 27, no. 2, pp. 123–140, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Mathieux, H. Marotte, L. Battistini, A. Sarrazin, M. Berthier, and P. Miossec, “Early occupational therapy programme increases hand grip strength at 3 months: results from a randomised, blind, controlled study in early rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 3, pp. 400–403, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. D. L. Scott, K. Pugner, K. Kaarela et al., “The links between joint damage and disability in rheumatoid arthritis,” Rheumatology, vol. 39, no. 2, pp. 122–132, 2000. View at Google Scholar · View at Scopus
  4. T. Pincus, “Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials,” Journal of Clinical Epidemiology, vol. 41, no. 11, pp. 1037–1041, 1988. View at Google Scholar · View at Scopus
  5. P. Emery, F. C. Breedveld, M. Dougados, J. R. Kalden, M. H. Schiff, and J. S. Smolen, “Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide,” Annals of the Rheumatic Diseases, vol. 61, no. 4, pp. 290–297, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. J. R. O'Dell, “Treating rheumatoid arthritis early: a window of opportunity?” Arthritis and Rheumatism, vol. 46, no. 2, pp. 283–285, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Schett and G. S. Firestein, “Mr Outside and Mr Inside: classic and alternative views on the pathogenesis of rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 69, no. 5, pp. 787–789, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Fouque-Aubert, S. Boutroy, H. Marotte et al., “Assessment of hand bone loss in rheumatoid arthritis by high-resolution peripheral quantitative CT,” Annals of the Rheumatic Diseases, vol. 69, no. 9, pp. 1671–1676, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. A. Van Leeuwen, M. H. Van Rijswijk, D. M. F. M. Van der Heijde et al., “The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease,” British Journal of Rheumatology, vol. 32, no. 6, pp. 9–13, 1993. View at Google Scholar · View at Scopus
  10. K. Redlich, S. Hayer, A. Maier et al., “Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin,” Arthritis and Rheumatism, vol. 46, no. 3, pp. 785–792, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Zwerina, S. Hayer, M. Tohidast-Akrad et al., “Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction,” Arthritis and Rheumatism, vol. 50, no. 1, pp. 277–290, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Karsdal, A. C. Bay-Jensen, D. J. Leeming, K. Henriksen, and C. Christiansen, “Quantification of “end products” of tissue destruction in inflammation may reflect convergence of cytokine and signaling pathways—implications for modern clinical chemistry,” Biomarkers, vol. 18, no. 5, pp. 375–378, 2013. View at Google Scholar
  13. P. E. Lipsky, D. M. van der Heijde, E. W. St Clair et al., “Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group,” The New England Journal of Medicine, vol. 343, no. 22, pp. 1594–1602, 2000. View at Google Scholar
  14. M. C. Genovese, J. M. Bathon, R. W. Martin et al., “Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes,” Arthritis and Rheumatism, vol. 46, no. 6, pp. 1443–1450, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. E. C. Keystone, A. F. Kavanaugh, J. T. Sharp et al., “Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial,” Arthritis and Rheumatism, vol. 50, no. 5, pp. 1400–1411, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. D. T. Felson, J. S. Smolen, G. Wells et al., “American college of rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials,” Arthritis and Rheumatism, vol. 63, no. 3, pp. 573–586, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Lillegraven, F. H. M. Prince, N. A. Shadick et al., “Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort,” Annals of the Rheumatic Diseases, vol. 71, no. 5, pp. 681–686, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Foltz, F. Gandjbakhch, F. Etchepare et al., “Power doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity,” Arthritis and Rheumatism, vol. 64, no. 1, pp. 67–76, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. M. A. Quinn, P. G. Conaghan, P. J. O'Connor et al., “Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial,” Arthritis and Rheumatism, vol. 52, no. 1, pp. 27–35, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. M. A. Karsdal, T. Woodworth, K. Henriksen et al., “Biochemical markers of ongoing joint damage in rheumatoid arthritis—current and future applications, limitations and opportunities,” Arthritis Research and Therapy, vol. 13, no. 2, article 215, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. J. D. Isaacs and G. Ferraccioli, “The need for personalised medicine for rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 70, no. 1, pp. 4–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Okada, H. Nagase, and E. D. Harris Jr., “A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization,” The Journal of Biological Chemistry, vol. 261, no. 30, pp. 14245–14255, 1986. View at Google Scholar · View at Scopus
  23. L. A. Walakovits, V. L. Moore, N. Bhardwaj, G. S. Gallick, and M. W. Lark, “Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury,” Arthritis and Rheumatism, vol. 35, no. 1, pp. 35–42, 1992. View at Google Scholar · View at Scopus
  24. E. M. Gravallese, J. M. Darling, A. L. Ladd, J. N. Katz, and L. H. Glimcher, “In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium,” Arthritis and Rheumatism, vol. 34, no. 9, pp. 1076–1084, 1991. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Constantin, V. Lauwers-Cancès, F. Navaux et al., “Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: association with severity and progression of rheumatoid arthritis in a prospective study,” Arthritis and Rheumatism, vol. 46, no. 7, pp. 1754–1762, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Chen, N. B. Nixon, P. T. Dawes, and D. L. Mattey, “Influence of variations across the MMP-1 and-3 genes on the serum levels of MMP-1 and-3 and disease activity in rheumatoid arthritis,” Genes and Immunity, vol. 13, no. 1, pp. 29–37, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Yamanaka, Y. Matsuda, M. Tanaka et al., “Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis,” Arthritis & Rheumatology, vol. 43, no. 4, pp. 852–858, 2000. View at Google Scholar
  28. P. Garnero, E. Gineyts, S. Christgau, B. Finck, and P. D. Delmas, “Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis,” Arthritis & Rheumatology, vol. 46, no. 1, pp. 21–30.
  29. A. Mamehara, T. Sugimoto, D. Sugiyama et al., “Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs,” Kobe Journal of Medical Sciences, vol. 56, no. 3, pp. E98–E107, 2010. View at Google Scholar · View at Scopus
  30. M. M. T. M. Ally, B. Hodkinson, P. W. A. Meyer, E. Musenge, M. Tikly, and R. Anderson, “Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis,” Mediators of Inflammation, vol. 2013, Article ID 183653, 6 pages, 2013. View at Publisher · View at Google Scholar
  31. M. Houseman, C. Potter, N. Marshall et al., “Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up,” Arthritis Research and Therapy, vol. 14, no. 1, article R30, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Huang, B. Xie, Q. Li et al., “Infliximab reduces CD147, MMP-3, and MMP-9 expression in peripheral blood monocytes in patients with active rheumatoid arthritis,” European Journal of Pharmacology, vol. 698, no. 1–3, pp. 429–434, 2013. View at Google Scholar
  33. M. E. Weinblatt, E. C. Keystone, D. E. Furst et al., “Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial,” Arthritis and Rheumatism, vol. 48, no. 1, pp. 35–45, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Funahashi, S. Koyano, T. Miura, T. Hagiwara, K. Okuda, and T. Matsubara, “Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level,” Modern Rheumatology, vol. 19, no. 5, pp. 507–512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Kanbe, J. Chiba, and A. Nakamura, “Immunohistological analysis of synovium treated with abatacept in rheumatoid arthritis,” Rheumatology International, vol. 33, no. 7, pp. 1883–1887, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Urata, R. Uesato, D. Tanaka, Y. Nakamura, and S. Motomura, “Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study,” Annals of the Rheumatic Diseases, vol. 71, no. 4, pp. 534–540, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. S.-Y. Kawashiri, A. Kawakami, Y. Ueki et al., “Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab,” Joint Bone Spine, vol. 77, no. 5, pp. 418–420, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Nishimoto, K. Amano, Y. Hirabayashi et al., “Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study,” Modern Rheumatology, vol. 24, no. no1, pp. 17–25, 2014. View at Google Scholar
  39. E. Gineyts, P. Garnero, and P. D. Delmas, “Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation,” Rheumatology, vol. 40, no. 3, pp. 315–323, 2001. View at Google Scholar · View at Scopus
  40. M. Takahashi, K. Kushida, H. Hoshino et al., “Concentrations of pyridinoline and deoxypyridinoline in joint tissues from patients with osteoarthritis or rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 55, no. 5, pp. 324–327, 1996. View at Google Scholar · View at Scopus
  41. H. Marotte, E. Gineyts, P. Miossec, and P. D. Delmas, “Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 7, pp. 1197–1200, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. J. K. Sandhu, S. Robertson, H. C. Birnboim, and R. Goldstein, “Distribution of protein nitrotyrosine in synovial tissues of patients with rheumatoid arthritis and osteoarthritis,” Journal of Rheumatology, vol. 30, no. 6, pp. 1173–1181, 2003. View at Google Scholar · View at Scopus
  43. P. Richardot, N. Charni-Ben Tabassi, L. Toh et al., “Nitrated type III collagen as a biological marker of nitric oxide-mediated synovial tissue metabolism in osteoarthritis,” Osteoarthritis and Cartilage, vol. 17, no. 10, pp. 1362–1367, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. N. C.-B. Tabassi, P. Richardot, L. Toh et al., “Circulating nitrated N-telopeptide of type III collagen (IIINys) as a biochemical marker of oxidative-related synovial tissue metabolism in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 3, pp. 451–452, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. B. Goldring and K. B. Marcu, “Cartilage homeostasis in health and rheumatic diseases,” Arthritis Research and Therapy, vol. 11, no. 3, article 224, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Christgau, P. Garnero, C. Fledelius et al., “Collagen type II C-telopeptide fragments as an index of cartilage degradation,” Bone, vol. 29, no. 3, pp. 209–215, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Garnero, R. Landewé, M. Boers et al., “Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study,” Arthritis and Rheumatism, vol. 46, no. 11, pp. 2847–2856, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Saxne and D. Heinegard, “Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood,” British Journal of Rheumatology, vol. 31, no. 9, pp. 583–591, 1992. View at Google Scholar · View at Scopus
  49. M. L. E. Andersson, B. Svensson, I. F. Petersson et al., “Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis,” BMC Musculoskeletal Disorders, vol. 14, p. 229, 2013. View at Google Scholar
  50. A. F. Christensen, T. Lottenburger, H. M. Lindegaard, K. Junker, K. Hørslev-Petersen, and P. Junker, “Circadian pattern and the effect of standardized physical exercise on procollagen IIA N-peptide (PIIANP) in rheumatoid arthritis at different stages and in healthy individuals,” Biomarkers, vol. 15, no. 1, pp. 80–85, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. E. Seeman and P. D. Delmas, “Bone quality—the material and structural basis of bone strength and fragility,” The New England Journal of Medicine, vol. 354, no. 21, pp. 2212–2261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. P. Garnero, M. Ferreras, M. A. Karsdal et al., “The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation,” Journal of Bone and Mineral Research, vol. 18, no. 5, pp. 859–867, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. M.-L. Sassi, H. Eriksen, L. Risteli et al., “Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K,” Bone, vol. 26, no. 4, pp. 367–373, 2000. View at Publisher · View at Google Scholar · View at Scopus
  54. P. Garnero and P. D. Delmas, “Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers,” Current Opinion in Rheumatology, vol. 16, no. 4, pp. 428–434, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. P. Garnero, P. Jouvenne, N. Buchs, P. D. Delmas, and P. Miossec, “Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products,” Bone, vol. 24, no. 4, pp. 381–385, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Fouque-Aubert, S. Boutroy, H. Marotte et al., “Assessment of hand bone loss in rheumatoid arthritis by high-resolution peripheral quantitative CT,” Annals of the Rheumatic Diseases, vol. 69, no. 9, pp. 1671–1676, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Aschenberg, S. Finzel, S. Schmidt et al., “Catabolic and anabolic periarticular bone changes in patients with rheumatoid arthritis: a computed tomography study on the role of age, disease duration and bone markers,” Arthritis Research & Therapy, vol. 15, no. 3, p. R62, 2013. View at Google Scholar
  58. A. Krabben, R. Knevel, T. W. J. Huizinga, G. Cavet, and A. H. M. van der Helm-van, “Serum pyridinoline levels and prediction of severity of joint destruction in rheumatoid arthritis,” The Journal of Rheumatology, vol. 40, no. 8, pp. 1303–1306, 2013. View at Google Scholar
  59. X. Le Loët, M. Brazier, O. Mejjad et al., “Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: a simple model of prediction from a conservatively treated community-based inception cohort,” Arthritis care & research, vol. 62, no. 12, pp. 1739–1747, 2010. View at Google Scholar · View at Scopus
  60. F. Chopin, P. Garnero, A. Le Henanff et al., “Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 67, no. 3, pp. 353–357, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Marotte and P. Miossec, “Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy,” Biologics, vol. 2, no. 4, pp. 663–669, 2008. View at Google Scholar · View at Scopus
  62. M. Vis, E. A. Havaardsholm, G. Haugeberg et al., “Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 65, no. 11, pp. 1495–1499, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. M. A. Karsdal, G. Schett, P. Emery et al., “IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522),” Seminars in Arthritis and Rheumatism, vol. 42, no. 2, pp. 131–139, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. P. J. Bekker, D. L. Holloway, A. S. Rasmussen et al., “A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004,” Journal of Bone and Mineral Research, vol. 20, no. 12, pp. 2275–2282, 2005. View at Google Scholar · View at Scopus
  65. S. B. Cohen, R. K. Dore, N. E. Lane et al., “Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial,” Arthritis and Rheumatism, vol. 58, no. 5, pp. 1299–1309, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. J. W. Peabody, V. Strand, R. Shimkhada, R. Lee, and D. Chernoff, “Impact of rheumatoid arthritis disease activity test on clinical practice,” PloS ONE, vol. 8, no. 5, 2013. View at Publisher · View at Google Scholar
  67. S. Hirata, L. Dirven, Y. Shen et al., “A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study,” Rheumatology, vol. 52, no. 7, pp. 1202–1207, 2013. View at Google Scholar
  68. A. H. M. van der Helm-van, R. Knevel, G. Cavet, T. W. J. Huizinga, and D. J. Haney, “An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression,” Rheumatology, vol. 52, no. 5, pp. 839–846, 2013. View at Google Scholar
  69. M. Vermeer, H. H. Kuper, M. Hoekstra et al., “Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study,” Arthritis and Rheumatism, vol. 63, no. 10, pp. 2865–2872, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. P. Miossec, C. L. Verweij, L. Klareskog et al., “Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies,” Annals of the Rheumatic Diseases, vol. 70, no. 10, pp. 1713–1718, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. G. Ferraccioli, S. Alivernini, and E. Gremese, “Biomarkers of joint damage in rheumatoid arthritis: where are we in 2013?” The Journal of Rheumatology, vol. 40, no. 8, pp. 1244–1246.